Lung cancer is the most commonly diagnosed cancer in both men and women and has the highest incidence and mortality rate among all cancers in the world. In recent years immunotherapy has become a game-changer in the treatment of cancer. Here, we present a patient with metastatic Non-Small Cell right lung carcinoma who was treated with pembrolizumab and achieved a very good response. This case highlights the efficacy of neoadjuvant pembrolizumab on metastatic lung carcinoma which provides a clinically meaningful therapeutic option for the future.